Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 62Lymphoid 13Other hematologic neoplasm 4Genitourinary 4Thoracic 3Gynecologic 2Tumor-Agnostic 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms 1

Interventions

Cisplatin 136Cetuximab 101pembrolizumab 83Radiotherapy 62Carboplatin 57Radiotherapy, Intensity-Modulated 54Fluorouracil 47Docetaxel 47Nivolumab 44Paclitaxel 37Radiation 21Erlotinib Hydrochloride 19durvalumab 18Platinum 15Ipilimumab 14Gemcitabine 13lenvatinib 12Drug Therapy 12Bevacizumab 12Albumin-Bound Paclitaxel 12vandetanib 11Pemetrexed 11Magnetic Resonance Spectroscopy 111,2-diaminocyclohexaneplatinum II citrate 11Radiosurgery 10Everolimus 10tremelimumab 9epacadostat 9Surgical Procedures, Operative 9Sorafenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × carfilzomib × Head & Neck × Clear all
NCT02047253 2018-12-19

Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment

University of Alabama at Birmingham

Phase 2 Completed
28 enrolled 12 charts
GenitourinaryHead & Neck

Salivary Gland Adenoma, Pleomorphic, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡